The Rationale for Bruton Tyrosine Kinase Inhibition in B-Cell Lymphomas

B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.

Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.

Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.